Synthesis and Evaluation of Analogues of N-Phthaloyl-l-tryptophan (RG108) as Inhibitors of DNA Methyltransferase 1
- 9 January 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (2) , 421-434
Abstract
DNA methyltransferases (DNMT) are promising drug targets in cancer provided that new, more specific, and chemically stable inhibitors are discovered. Among the non-nucleoside DNMT inhibitors, N-phthaloyl-l-tryptophan 1 (RG108) was first identified as inhibitor of DNMT1. Here, 1 analogues were synthesized to understand its interaction with DNMT. The indole, carboxylate, and phthalimide moieties were modified. Homologated and conformationally constrained analogues were prepared. The latter were synthesized from prolinohomotryptophan derivatives through a methodology based amino–zinc–ene–enolate cyclization. All compounds were tested for their ability to inhibit DNMT1 in vitro. Among them, constrained compounds 16–18 and NPys derivatives 10–11 were found to be at least 10-fold more potent than the reference compound. The cytotoxicity on the tumor DU145 cell line of the most potent inhibitors was correlated to their inhibitory potency. Finally, docking studies were conducted in order to understand their binding mode. This study provides insights for the design of the next-generation of DNMT inhibitors.Keywords
This publication has 56 references indexed in Scilit:
- Epigenetic modifications and human diseaseNature Biotechnology, 2010
- Epigenetic modifications as therapeutic targetsNature Biotechnology, 2010
- CpG islands – ‘A rough guide’FEBS Letters, 2009
- An operational definition of epigenetics: Figure 1.Genes & Development, 2009
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Phenotypic plasticity and the epigenetics of human diseaseNature, 2007
- Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genomeNature Genetics, 2007
- The Epigenomics of CancerCell, 2007
- Promoter Hypermethylation--Can This Change Alone Ever Designate True Tumor Suppressor Gene Function?JNCI: Journal of the National Cancer Institute, 2001
- Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastomaHuman Genetics, 1989